FDA
-
-
-
-
-
-
-
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
-
-
-
-
-
-
-
Silo Pharma selects Allucent for FDA drug application support
-
-
-
-
-
-
-
Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio
-
-
-
-
-
-
-
Silo Pharma expects preclinical data for PTSD drug SPC-15 within 90 days
-
-
-
-
-
-
-
Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15
-
-
-
-
-
-
-
Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
-
-
-
-
-
-
-
Silo Pharma, Inc. (SILO) Announces Provisional Patent Filing for PTSD Treatment
-
324,764 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

